Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 23,440,000 shares, a growth of 16.5% from the April 15th total of 20,120,000 shares. Based on an average daily volume of 4,450,000 shares, […]
Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Hold Rating from Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research report issued on Tuesday, April 30th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter. […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) CEO Lonnel Coats bought 40,000 shares of Lexicon Pharmaceuticals stock in a transaction on Thursday, June 22nd. The stock was acquired at an average price of $2.31 per share, for a total transaction of $92,400.00. Following the purchase, the chief executive officer now owns 784,359 shares of the […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) was up 10.2% on Wednesday . The stock traded as high as $2.95 and last traded at $2.93. Approximately 3,253,692 shares were traded during trading, an increase of 195% from the average daily volume of 1,103,374 shares. The stock had previously closed at $2.66. Analyst Upgrades and Downgrades […]